Drugs / SHR0302Base
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06790862 | Feb 2025 → Mar 2026 overdue | vitiligo | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR0302Base | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06790862 ↗ |